Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT00979134
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies
Associate Professor of Medicine (Oncology)
Inclusion Criteria:
- Minimum life expectancy of 12 weeks
- The presence of a solid, malignant tumour that is resistance to standard therapies or
for which no standard therapies exist
- In the expansion for the study patients must have a tumour at least 1cm in size that
can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor
company for testing of FGFR1 and/or 2 amplification
- Expansion, 5 groups of advanced cancer
- Solid tumours,FGFR1 and/or FGFR2 gene amplified
- Squamous NSCLC, FGFR1 gene low & high amplified
- Gastric adenocarcinoma, including the lower oesophagus/gastro-oesophageal junction,
FGFR2 gene low & high amplified
- Aged at least 25 years
Exclusion Criteria:
- Treatment with any other chemotherapy, immunotherapy or anticancer agents within 3
weeks before the first dose of study
- An inability to be able to take the study medication
- A bad reaction to AZD4547 or any drugs similar to it in structure or class.
drug: AZD4547
drug: AZD4547
drug: AZD4547
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061